Senseonics (NYSE:SENS) shares are off nearly -7% today after the continuous glucose monitor maker revealed plans for a stock and debt offerings and released its preliminary second-quarter sales numbers.
Germantown, Md.-based Senseonics, which developed the Eversense implantable CGM, said it plans to float $25 million in stock (plus a 30-day, $3.8 million underwriters option) and $80 million in senior notes.
Proceeds from the debt offering, of 5.25% convertible senior notes due 2025, are earmarked for buying back $29.0 million in 5.25% convertible senior subordinated notes due 2023.
Senseonics also said it expects to log second-quarter sales of $4.4 million to $4.7 million, in-line with the consensus forecast of $4.5 million.
“We are pleased with the progress our team has made in the U.S. since introducing the Bridge patient access program. We have seen utilization increase, which reinforces the clinical value that the Eversense CGM system provides to patients and the broader healthcare system,” president & CEO Tim Goodnow said in prepared remarks. “Patient demand is strong and we are successfully accelerating shipments and prescriptions globally, thus increasing our confidence in greater adoption of Eversense in the second half of the year.”
SENS shares slid as much as -11.3% today on the news and were down -4.2% at $1.61 apiece today in mid-morning trading.